The standard diagnostic workup of GIST tumors now includes assessment of c-Kit abnormalities and a number of c-kit inhibitors, such as imatinib, have demonstrated significant activity in tumors with these mutations (15). This evidence concerns the gene KIT and gastrointestinal stromal tumor.